Haleon shares fall 3.4% as revenue growth falls short of the company's own medium-term target

Core Viewpoint - Haleon shares declined by 3.4% after reporting organic revenue growth of 3%, which fell short of the company's medium-term target of 4-6% [2][3] Group 1: Revenue Performance - Organic growth was driven down by a weak cold and flu season and cautious consumer behavior in North America, which accounts for 35% of revenues, resulting in a contraction of 0.4% [3] - The mild winter negatively impacted revenue, stripping an estimated 40 basis points from the full-year growth and 150 basis points from the fourth quarter, particularly affecting the Robitussin brand [3] Group 2: Profitability Metrics - Adjusted operating profit increased by 10.5% organically to £2.526 billion, with margins expanding by 160 basis points [4] - Free cash flow reached £1.913 billion, supported by a supply chain productivity program that has reduced SKU counts by 26% and aims for £800 million in gross savings over five years [4] Group 3: Future Guidance - For 2026, the company is guiding for organic revenue growth of 3-5% and plans to return £500 million to shareholders through buybacks [4] - The dividend has increased by 7.6% to 7.1p, indicating a commitment to shareholder returns [4] Group 4: Market Position - The CEO noted that 60% of the business gained or maintained market share, suggesting that the brands remain competitive despite the challenges faced [5]